Versant Venture Capital Vi, L.P. Lava Therapeutics Nv (LVTX) insider trading activity

Versant Venture Capital Vi, L.P. is of LAVA Therapeutics NV. Currently has a direct ownership of 0 shares of LVTX, which is worth approximately $0. The most recent transaction as insider was on Sep 19, 2025, when has been sold 2,370,533 shares (Common Stock) at a price of $1.4 per share, resulting in proceeds of $3,318,746. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

n/a 3M change

n/a 12M change

Total Value Held $0

Versant Venture Capital VI, L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 19 2025	SELL Open market or private sale	$3,318,746 $1.4 p/Share	2,370,533 Reduced 100.0%	0 Common Stock
Sep 18 2025	SELL Open market or private sale	$527,199 $1.44 p/Share	366,111 Reduced 13.38%	2,370,533 Common Stock
Sep 17 2025	SELL Open market or private sale	$540,580 $1.49 p/Share	362,806 Reduced 11.71%	2,736,644 Common Stock
Sep 16 2025	SELL Open market or private sale	$470,791 $1.53 p/Share	307,707 Reduced 9.03%	3,099,450 Common Stock

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

ALGS

Aligos Therapeutics, Inc. Healthcare

> 10% Shareholder

OYST

Oyster Point Pharma, Inc. Healthcare

> 10% Shareholder

IPSC

Century Therapeutics, Inc. Healthcare

> 10% Shareholder

GLUE

Monte Rosa Therapeutics, Inc. Healthcare

GRPH

Graphite Bio, Inc. Healthcare

CTNM

Contineum Therapeutics, Inc.

> 10% Shareholder

TPST

Tempest Therapeutics, Inc. Healthcare

VVC